Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Matutes, E; Pickl, WF; Van't Veer, M; Morilla, R; Swansbury, J; Strobl, H; Attarbaschi, A; Hopfinger, G; Ashley, S; Bene, MC; Porwit, A; Orfao, A; Lemez, P; Schabath, R; Ludwig, WD.
Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification.
Blood. 2011; 117(11):3163-3171
Doi: 10.1182/blood-2010-10-314682
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Strobl Herbert
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The features of 100 mixed-phenotype acute leukemias (MPALs), fulfilling WHO 2008 criteria, are documented. Myeloid and T-lineage features were demonstrated by cytoplasmic myeloperoxidase and CD3; B-lineage features were demonstrated by at least 2 B-lymphoid markers. There were 62 men and 38 women; 68% were adults. Morphology was consistent with acute lymphoblastic leukemia (ALL; 43%), acute myeloid leukemia (AML; 42%), or inconclusive (15%). Immunophenotyping disclosed B + myeloid (59%), T + myeloid (35%), B + T (4%), or trilineage (2%) combinations. Cytogenetics evidenced t(9;22)/(Ph(+)) (20%), 11q23/MLL rearrangements (8%), complex (32%), aberrant (27%), or normal (13%) karyotypes. There was no correlation between age, morphology, immunophenotype, or cytogenetics. Response to treatment and outcome were available for 67 and 70 patients, respectively; 27 received ALL, 34 AML, 5 a combination of ALL + AML therapy, and 1 imatinib. ALL treatment induced a response in 85%, AML therapy in 41%; 3 of 5 patients responded to the combination therapy. Forty (58%) patients died, 33 of resistant disease. Overall median survival was 18 months and 37% of patients are alive at 5 years. Age, Ph(+), and AML therapy were predictors for poor outcome (P < .001; P = .002; P = .003). MPAL is confirmed to be a poor-risk disease. Adults and Ph(+) patients should be considered for transplantation in first remission.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- B-Lymphocytes - pathology
- Blast Crisis - immunology Blast Crisis - pathology
- Cell Differentiation -
- Cell Lineage -
- Cytogenetic Analysis -
- Female -
- Flow Cytometry -
- Humans -
- Immunophenotyping -
- Infant -
- Male -
- Precursor Cell Lymphoblastic Leukemia-Lymphoma - classification Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy
- T-Lymphocytes - pathology
- Treatment Outcome -
- World Health Organization -